Drug Information

Drug (ID: DG00395) and It's Reported Resistant Information

• Name: Orthocresol
• Synonyms: O-cresol; 2-Methylphenol; 95-48-7; Orthocresol; 2-hydroxytoluene; Phenol, 2-methyl-; 2-Cresol; o-methylphenol; o-Cresylic acid; o-Oxytoluene; o-Toluol; o-Hydroxytoluene; o-Methylphenylol; 1-Hydroxy-2-methylbenzene; ortho-cresol; o-Kresol; 2-methyl phenol; Cresol, ortho-; Cresol, o-; o-Kresol [German]; 2-Hydroxy-1-methylbenzene; Cresylic acid; 2-methyl-phenol; Cresol, o-isomer; hydroxy toluene; Phenol, methyl-; UNII-YW84DH5I7U; NSC 23076; Cresol mixture of isomers; 1-Methyl-2-hydroxybenzene; YW84DH5I7U; CHEBI:28054; MFCD00002226; TOLUENE,2-HYDROXY (ORTHO-CRESOL); o-Cresol [UN2076] [Poison, Corrosive]; DSSTox_CID_1808; Cresol mixture of isomers;Methylphenol;Tricresol; DSSTox_RID_76341; WLN: QR B1; DSSTox_GSID_21808; CAS-95-48-7; Orthocresol [NF]; Cresols are organic compounds which are methylphenols. They are a widely occurring natural and manufactured group of aromatic organic compounds, which are categorized as phenols.; CCRIS 646; FEMA No. 3480; HSDB 1813; EINECS 202-423-8; ortho cresol; Methyl phenol; 2-methyiphenol; AI3-00137; JZ0; O-Cresol,(S); Carvacrol derivative, 9; o-Cresol, >=99%; bmse000433; UN 2076 (Related); EC 202-423-8; 2-Methylphenol (o-cresol); ortho-cresol,2-methylphenol; SCHEMBL16002; MLS002454426; o-Cresol, analytical standard; BIDD:ER0677; CHEMBL46931; 3C7H8O; DTXSID8021808; FEMA 3480; BDBM248166; HMS2268O24; LABOTEST-BB LTBB001400; ZINC901022; o-Cresol, for synthesis, 99.3%; 2-Methylphenol, analytical standard; NSC23076; NSC36809; Tox21_202305; Tox21_300021; NSC-23076; NSC-36809; STL194295; o-Cresol, ReagentPlus(R), >=99%; AKOS000119021; AS00217; MCULE-4124485112; NCGC00091534-01; NCGC00091534-02; NCGC00091534-03; NCGC00091534-04; NCGC00254140-01; NCGC00259854-01; o-Cresol, SAJ first grade, >=97.0%; SMR001252248; 2-Methylphenol 100 microg/mL in Methanol; FT-0656046; Z3651; 7520-EP2277867A2; 7520-EP2280003A2; 7520-EP2292227A2; 7520-EP2295426A1; 7520-EP2295427A1; 7520-EP2295435A1; 7520-EP2298751A2; 7520-EP2302015A1; 7520-EP2305683A1; 7520-EP2308861A1; 7520-EP2311839A1; 7520-EP2314584A1; 7520-EP2314589A1; 7520-EP2316470A2; 7520-EP2316832A1; 7520-EP2316833A1; 7520-EP2316837A1; C01542; 19034-EP2311811A1; 19034-EP2314576A1; 28670-EP2279750A1; 28670-EP2284146A2; 28670-EP2284147A2; 28670-EP2284165A1; 28670-EP2287159A1; 28670-EP2305673A1; 28670-EP2308838A1; 28670-EP2308865A1; 28670-EP2308877A1; 28670-EP2311815A1; 28670-EP2311834A1; 28670-EP2314579A1; 28670-EP2372017A1; 45193-EP2311821A1; 93911-EP2269977A2; 93911-EP2305625A1; 1-Hydroxyl 2-Methyl Benzene, 2-Hydroxyl Toluene; Q312708; J-006098; J-523819; F0001-2271; UNII-3JYG22FD73 component QWVGKYWNOKOFNN-UHFFFAOYSA-N; UNII-GF3CGH8D7Z component QWVGKYWNOKOFNN-UHFFFAOYSA-N
• Formula: C7H8O
• IsoSMILES: CC1=CC=CC=C1O
• InChI: 1S/C7H8O/c1-6-4-2-3-5-7(6)8/h2-5,8H,1H3
• InChIKey: QWVGKYWNOKOFNN-UHFFFAOYSA-N
• PubChem CID: 335

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Melanoma [ICD-11: 2C30]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Growth arrest specific 5 (GAS5) [1]

• Sensitive Disease: Melanoma [ICD-11: 2C30.0]
• Molecule Alteration: Expression; Up-regulation

Differential expression of the molecule in resistant disease

• Classification of Disease: Melanoma [ICD-11: 2C30]
• The Specified Disease: Skin cutaneous melanoma
• The Studied Tissue: Skin
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 3.29E-02; Fold-change: 1.53E-01; Z-score: 2.14E+00
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• In Vitro Model: A375 cells; Skin; Homo sapiens (Human); CVCL_0132
• In Vitro Model: A431 cells; Skin; Homo sapiens (Human); CVCL_0037
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: MTT assay; Flow cytometry assay
• Mechanism Description: 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Overexpression of LncRNA GAS5 inhibited cell proliferation and promoted cell apoptosis in skin cancer cells.

Skin squamous cell carcinoma [ICD-11: 2C31]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Growth arrest specific 5 (GAS5) [1]

• Sensitive Disease: Skin squamous cell carcinoma [ICD-11: 2C31.2]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Activation; hsa04210
• Cell Pathway Regulation: Cell proliferation; Inhibition; hsa05200
• In Vitro Model: A375 cells; Skin; Homo sapiens (Human); CVCL_0132
• In Vitro Model: A431 cells; Skin; Homo sapiens (Human); CVCL_0037
• In Vivo Model: Nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: MTT assay; Flow cytometry assay
• Mechanism Description: 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Overexpression of LncRNA GAS5 inhibited cell proliferation and promoted cell apoptosis in skin cancer cells.

References

• Ref 1: 2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells. Cell Death Dis. 2017 Mar 2;8(3):e2638. doi: 10.1038/cddis.2017.66.